Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PHGDH | O43175 | 2/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5118465 | 0.92 | KDM4E (0.51) | HSD11B1TRPA1KDM4EGAATRPV1 | |
| SCHEMBL1457262 | 0.90 | TRPA1 (0.42) | SMN1; SMN2HTTKMT2AHSD11B1TRPA1 | |
| SCHEMBL5119463 | 0.88 | TRPA1 (0.47) | SMN1; SMN2MAPTLMNATRPA1GAA | |
| SCHEMBL1457626 | 0.88 | TRPA1 (0.45) | HSD11B1TRPA1KDM4EGAATRPV1 | |
| SCHEMBL5121480 | 0.87 | TRPA1 (0.51) | MAPTLMNATRPA1GAATRPV1 | |
| SCHEMBL5114396 | 0.87 | PHGDH (0.44) | KMT2AMAPTLMNATRPA1KDM4E | |
| SCHEMBL5119805 | 0.86 | ALDH1A1 (0.50) | SMN1; SMN2KMT2AMAPTLMNAKDM4E | |
| SCHEMBL5125632 | 0.86 | TRPA1 (0.46) | KMT2AMAPTLMNATRPA1GAA | |
| SCHEMBL5115293 | 0.84 | TRPV1 (0.51) | MAPTTRPA1KDM4ETRPV1 | |
| SCHEMBL5120186 | 0.83 | KDM4E (0.52) | TRPA1KDM4ETRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214807-A1 | Substituted Spiro Compounds and their Use for Producing Drugs | GRUENENTHAL GMBH (DE) | 2008-09-04 | — | — | US | claimed |
| US-20080214807-A1 | Substituted Spiro Compounds and their Use for Producing Drugs | GRUENENTHAL GMBH (DE) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214807-A1 | Substituted Spiro Compounds and their Use for Producing Drugs | REN, PKD1, NR3C2 | SMN1; SMN2 4677/4885HTT 1428/4885KMT2A 4068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.